Thank you for subscribing!
Learn More about Next Investors - Experts in Biotech Stocks
Next Investors Archived Jul 10, 2018
Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.
Next Investors Archived Jun 26, 2018
Today’s company has created the first and only regulated medical device for the management of autism in a home setting.
Next Investors Archived Jun 07, 2018
Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Next Investors Archived May 21, 2018
BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.
Get expert stock analysis direct in your inbox
Next Investors Archived May 17, 2018
Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.
Next Investors Archived May 16, 2018
Creso Pharma (ASX:CPH) has today informed the market that it has entered into a joint venture with Cohen Propagation Nurseries Limited to operate a high quality medicinal cannabis growing facility in Israel.
Next Investors Archived Apr 12, 2018
MGC Pharmaceuticals (ASX:MXC) has wasted no time ramping up its game in 2018.
Next Investors Archived Mar 13, 2018
This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.
Next Investors Archived Mar 08, 2018
Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC | NASDAQ:IMRN) continues to progress its oral immunotherapies, to supply solutions for a growing unmet need.
Next Investors Archived Feb 23, 2018
Respiri (ASX:RSH) is leading the way in new technologies to better manage asthma, a chronic disease affecting more than 330 million worldwide.
Next Investors Archived Jan 18, 2018
While much of the business world shut down over the Christmas-New Year’s break, diversified cannabis healthcare company Creso Pharma (ASX:CPH) has been busy on a number of fronts.
Next Investors Archived Dec 04, 2017
It has been a major month for Creso Pharma (ASX:CPH) as it continues to make potentially market moving announcements.
Next Investors Archived Nov 23, 2017
MGC Pharmaceuticals (ASX:MXC) was the second company to originally emerge in the ASX cannabis corridor, and with a whip-smart team that’s put in serious hours in the industry-leading Israeli medicinal marijuana scene, this ASX junior is rapidly coming into its own.
Next Investors Archived Nov 15, 2017
This Australian-based developer of US FDA and Australia TGA approved natural and organic skin care products already has mainstream reach spanning over 15 countries, through its 100% natural and organic sunscreen Soleo Organics and is set to launch its organics sunscreen range into the US$10BN global suncare market.
Next Investors Archived Nov 14, 2017
Creso Pharma (ASX: CPH) has hit a major milestone with the launch of its first animal health product in Switzerland and Lichtenstein.
Next Investors Archived Aug 09, 2017
It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.
Next Investors Archived Jul 27, 2017
Creso Pharma (ASX:CPH) is now in the box seat to acquire 100% of Canadian-based Mernova Medicinal Inc., an acquisition that would position CPH as a Canadian producer of legal cannabis.
Next Investors Archived Jun 14, 2017
News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.
Join Our Mailing List
